Assignee
IMMUNOGEN INC
US202 patents
Top patents by PatentIndex Score
US7601354B2Oct 13, 2009
Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
IMMUNOGEN INC161 citations99
US7368565B2May 6, 2008
Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents
IMMUNOGEN INC239 citations99
US7303749B1Dec 4, 2007
Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
IMMUNOGEN INC226 citations99
US7276497B2Oct 2, 2007
Cytotoxic agents comprising new maytansinoids
IMMUNOGEN INC402 citations99
US6756397B2Jun 29, 2004
Prodrugs of CC-1065 analogs
IMMUNOGEN INC144 citations99
US6706708B2Mar 16, 2004
Cytotoxic agents comprising taxanes and their therapeutic use
IMMUNOGEN INC71 citations99
US6630579B2Oct 7, 2003
Cytotoxic agents comprising modified doxorubicins and daunorubicins and their therapeutic use
IMMUNOGEN INC547 citations99
US6596757B1Jul 22, 2003
Cytotoxic agents comprising polyethylene glycol-containing taxanes and their therapeutic use
IMMUNOGEN INC165 citations99
US6586618B1Jul 1, 2003
CC-1065 analog synthesis
IMMUNOGEN INC125 citations99
US6534660B1Mar 18, 2003
CC-1065 analog synthesis
IMMUNOGEN INC168 citations99
US6441163B1Aug 27, 2002
Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents
IMMUNOGEN INC690 citations99
US6436931B1Aug 20, 2002
Cytotoxic agents comprising taxanes and their therapeutic use
IMMUNOGEN INC184 citations99
US6340701B1Jan 22, 2002
Cytotoxic agents comprising taxanes and their therapeutic use
IMMUNOGEN INC271 citations99
US5846545ADec 8, 1998
Targeted delivery of cyclopropylbenzindole-containing cytotoxic drugs
IMMUNOGEN INC531 citations99
US5585499ADec 17, 1996
Cyclopropylbenzindole-containing cytotoxic drugs
IMMUNOGEN INC541 citations99
US5475092ADec 12, 1995
Cell binding agent conjugates of analogues and derivatives of CC-1065
IMMUNOGEN INC668 citations99
US9670279B2Jun 6, 2017
Folate receptor 1 antibodies and immunoconjugates and uses thereof
IMMUNOGEN INC26 citations98
US9133275B2Sep 15, 2015
Folate receptor 1 antibodies and immunoconjugates and uses thereof
IMMUNOGEN INC45 citations98
US7851432B2Dec 14, 2010
Cytotoxic agents comprising new maytansinoids
IMMUNOGEN INC54 citations98
US7557189B2Jul 7, 2009
Anti-CD33 antibodies and method for treatment of acute myeloid leukemia using the same
IMMUNOGEN INC109 citations98
US7473796B2Jan 6, 2009
Cytotoxic agents comprising new maytansinoids
IMMUNOGEN INC55 citations98
US7388026B2Jun 17, 2008
Prodrugs of CC-1065 analogs
IMMUNOGEN INC68 citations98
US7342110B2Mar 11, 2008
Anti-CD33 antibodies and method for treatment of acute myeloid leukemia using the same
IMMUNOGEN INC82 citations98
US7049316B2May 23, 2006
Prodrugs of CC-1065 analogs
IMMUNOGEN INC77 citations98
US6716821B2Apr 6, 2004
Cytotoxic agents bearing a reactive polyethylene glycol moiety, cytotoxic conjugates comprising polyethylene glycol linking groups, and methods of making and using the same
IMMUNOGEN INC359 citations98
US9359442B2Jun 7, 2016
Anti-CD33 antibodies and methods for treatment of acute myeloid leukemia using the same
IMMUNOGEN INC29 citations97
US7989598B2Aug 2, 2011
Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates and methods of making said conjugates
IMMUNOGEN INC46 citations97
US7374762B2May 20, 2008
Drug conjugate composition
IMMUNOGEN INC79 citations97
US6913748B2Jul 5, 2005
Cross-linkers with high reactivity and solubility and their use in the preparation of conjugates for targeted delivery of small molecule drugs
IMMUNOGEN INC209 citations97
US5416064AMay 16, 1995
Cytotoxic agents comprising maytansinoids and their therapeutic use
IMMUNOGEN INC1,261 citations97
US5208020AMay 4, 1993
Cytotoxic agents comprising maytansinoids and their therapeutic use
IMMUNOGEN INC2,372 citations97
US8383122B2Feb 26, 2013
Process for preparing purified drug conjugates
IMMUNOGEN INC40 citations96
US7811572B2Oct 12, 2010
Process for preparing purified drug conjugates
IMMUNOGEN INC73 citations96
US7655661B2Feb 2, 2010
Prodrugs of CC-1065 analogs
IMMUNOGEN INC35 citations96
US7655660B2Feb 2, 2010
Prodrugs of CC-1065 analogs
IMMUNOGEN INC39 citations96
US7514080B2Apr 7, 2009
Drug conjugate composition
IMMUNOGEN INC41 citations96
US7501120B2Mar 10, 2009
Drug conjugate composition
IMMUNOGEN INC42 citations96
US7276499B2Oct 2, 2007
Cytotoxic agents comprising taxanes and their therapeutic use
IMMUNOGEN INC58 citations96
US7097840B2Aug 29, 2006
Methods of treatment using anti-ErbB antibody-maytansinoid conjugates
IMMUNOGEN INC266 citations96
US7008942B2Mar 7, 2006
Cytotoxic agents comprising taxanes and their therapeutic use
IMMUNOGEN INC24 citations96
US7538195B2May 26, 2009
Anti-IGF-I receptor antibody
IMMUNOGEN INC57 citations95
US6333410B1Dec 25, 2001
Process for the preparation and purification of thiol-containing maytansinoids
IMMUNOGEN INC412 citations95
US10752683B2Aug 25, 2020
Folate receptor 1 antibodies and immunoconjugates and uses thereof
IMMUNOGEN INC13 citations94
US7494649B2Feb 24, 2009
Drug conjugate composition
IMMUNOGEN INC41 citations94
USRE39151EJun 27, 2006
Process for the preparation and purification of thiol-containing maytansinoids
IMMUNOGEN INC72 citations94
US6372738B2Apr 16, 2002
Cytotoxic agents comprising taxanes and their therapeutic use
IMMUNOGEN INC179 citations94
US7906545B2Mar 15, 2011
Prodrugs of CC-1065 analogs
IMMUNOGEN INC20 citations93
US7414073B2Aug 19, 2008
Cytotoxic agents containing novel potent taxanes and their therapeutic use
IMMUNOGEN INC42 citations93
US7411063B2Aug 12, 2008
Process for preparation of maytansinol
IMMUNOGEN INC31 citations93
US7329760B2Feb 12, 2008
CC-1065 analog synthesis
IMMUNOGEN INC31 citations93
Showing the top 50 of 202 patents by PatentIndex Score.